Lipfendra: A New Pill Taking on “Bad” Cholesterol

Pharmacy
1

lipfendra
lipfendra768×432 96 KB

For years, statins have been the backbone of hyperlipidemia management. But what happens when LDL cholesterol remains high despite treatment—or when patients need an alternative to injectable PCSK9 inhibitors?

Enter Lipfendra (enlicitide)—a newly approved oral drug that brings PCSK9 inhibition into a once-daily tablet.

What makes Lipfendra different?

Lipfendra is a PCSK9 inhibitor and the first FDA-approved PCSK9 inhibitor available as an oral tablet. It is indicated, along with diet and exercise, to reduce LDL-C in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

:microscope: Mechanism of action

Normally, PCSK9 binds to LDL receptors on liver cells and promotes their degradation. This reduces the liver’s ability to remove LDL-C from the bloodstream.

Enlicitide binds to PCSK9 → prevents PCSK9–LDL receptor interaction → preserves LDL receptors → increases hepatic LDL clearance → lowers circulating LDL-C.

:chart_decreasing: How effective is it?

In clinical trials, Lipfendra produced approximately 56% and 59% placebo-adjusted reductions in LDL-C at Week 24 in patients with cardiovascular risk/severe hypercholesterolemia and HeFH, respectively.

Why is this important?

Existing PCSK9 therapies have largely been injectable. A once-daily oral option could offer greater convenience for patients who require substantial additional LDL-C lowering.

However, Lipfendra is not simply a replacement for statins in every patient. Its approved role is to reduce LDL-C as an adjunct to diet and exercise, and its place in therapy will depend on the patient’s cardiovascular risk, LDL-C goals, previous treatment and tolerance.

Conclusion

Lipfendra represents an important development in lipid-lowering therapy: PCSK9 inhibition without an injection. Its approval shows how drug development is moving beyond traditional approaches to improve both LDL-C reduction and treatment convenience.

Do you think an effective oral PCSK9 inhibitor like Lipfendra could improve adherence compared with injectable PCSK9 therapies? Why or why not?

MBH/PS

4 Likes
2

Yes, I think oral PCSK9 inhibitor could improve adherence for some patients. Taking a daily tablet may feel more convenient and less intimidating than regular injections. But adherence will still depend on factors like cost, side effects, and how comfortable patients are with long-term treatment.

1 Like
3

Interesting development. Always good to see new options in lipid management. Thanks for the update.

1 Like
4

Absolutely, I think an oral PCSK9 inhibitor could improve adherence for some patients. A once-daily tablet may feel more convenient and less intimidating than regular injections, especially for patients who prefer oral medications.

1 Like
5

Yes, discoveries like this will help in making patient’s life more convenient.

1 Like
6

Really interesting development in lipid management. The idea of bringing PCSK9 inhibition into a once-daily oral tablet is especially promising for patients who find injectable therapies inconvenient. It’ll be interesting to see how this fits into everyday practice and whether the convenience actually translates into better long-term adherence.

1 Like